Scope and Claims Analysis for US Patent 11,679,086 (Transdermal Patches for Alzheimer’s Disease Using Donepezil-Containing Adhesive Matrix Drug Layers)
US Patent 11,679,086 is a US-method and delivery-oriented patent estate focused on transdermal patch architectures that combine (1) a composite backing layer with a defined three-layer laminate structure and (2) an adhesive matrix drug layer laminated to a cut-containing third polymer film layer. The claims are drafted to capture both (i) a general “method for treating Alzheimer’s disease” and (ii) a more specific “method for delivery of donepezil through skin,” with multiple dependent claim fallbacks that constrain layer materials, thicknesses, mechanical properties, and release liner embodiments.
What exactly does US 11,679,086 claim cover for transdermal donepezil treatment?
Core claim position (independent claim 1): The invention claims a method that involves providing a transdermal patch with a particular multi-layer composite backing and an adhesive matrix drug layer laminated to a cut-forming polymer film layer. The method then encompasses using that patch to treat Alzheimer’s disease.
Claim 1 elements that define infringement boundaries
Claim 1 requires all of the following structural components in the patch:
- Transdermal patch for Alzheimer’s treatment.
- Composite backing layer having three sub-layers in a defined contact arrangement:
- First layer: polymer fabric or polymer film with stretchability ≥ 5% in at least one direction.
- Second layer: one or more adhesive polymers.
- Third layer: one or more polymer films.
- Layer contacts:
- First layer and second layer are in contact.
- Second layer and third layer are in contact.
- Third layer contains cuts:
- Cuts are formed at least partially through the third layer.
- Adhesive matrix drug layer:
- Laminated to the third layer.
- Comprising a drug (explicitly donepezil in dependent claim 10).
Why this matters: The “composite backing” and “cuts at least partially through the third layer” are the primary technical anchors. Many generic or alternative patch products may use adhesive matrices, but if they do not include a third film layer with through-or-partial-through cuts in the specified laminate arrangement, claim 1 risk drops sharply.
Independent claim 13: delivery method with patch assembly recited
Claim 13 similarly requires:
- Composite backing layer with the same three-layer structure and cut-containing third polymer film.
- Adhesive drug layer comprising donepezil, laminated to the third layer.
- Release liner included in the patch.
- A delivery use step: donepezil delivered through skin after removing the release liner and applying to skin.
Practical boundary: Claim 13 ties together the delivery scenario and includes the release liner. If a product is sold without a release liner (rare for patches) or uses different liner architecture, claim 13 can be harder to assert. Claim 1 is broader because it does not require a release liner in the provided claim set.
How broad is the claim scope: what parts are limiting vs flexible?
Most limiting features
- Cut-containing third polymer film layer: “cuts formed at least partially through the layer” is a structural limitation tied to patch architecture.
- Defined three-layer backing adjacency: First-second contact and second-third contact.
- First layer stretchability ≥ 5% in at least one direction: constrains material selection and mechanical performance.
- Adhesive matrix drug layer laminated to the third layer: requires lamination interface with the cut-containing film.
More flexible features
- Drug identity is broad in claim 1 (any drug), but becomes donepezil in claim 10 and claim 13/14-20 family.
- Adhesive polymer families are enumerated but not necessarily exclusive; dependent claim language is open-ended through “selected from” lists (still constraining, but giving multiple embodiments).
- Thickness ranges are broad (backing sublayers and third layer thicknesses cover wide ranges typical of patch designs).
- First layer polymer chemistry includes multiple polymer families (polyesters, polyethylenes, polypropylenes, PVC, EVA, polyurethanes), and first layer can be woven/non-woven/laminate or polymer/metal laminate.
What are the key dependent claims that narrow the invention and create design-around options?
Mechanical stretchability and material composition
- Claim 3: first layer polymers selected from polyesters, polyethylenes, polypropylenes, PVC, EVA copolymers, and polyurethanes.
- Claim 4: first layer selected from woven polymer fabric, non-woven polymer fabric, polymer laminate, polymer/metal laminate.
- Claim 5: first layer thickness about 0.5–10 mil.
Design-around pressure points:
- If a competitor uses a non-stretchable backing below ≥5% stretch, claim 1’s first-layer property fails.
- If the competitor uses different backing compositions outside the enumerated list, it avoids at least claim 3/14-style dependent claim scope, though independent claim 1 may still be asserted depending on whether claim 1 requires those specific polymers (as provided, claim 1 does not limit to that list).
Adhesive polymers and their properties
- Claim 6: second layer polymer(s) have tensile strength <10 MPa and elongation ≥50% (where one or both parameters apply depending on claim construction; the text recites “at least one of (i) tensile strength <10 MPa and (ii) elongation ≥50%”).
- Claim 7: second layer adhesive polymers selected from acrylates/acrylate copolymers, polyisobutylene, silicone, polystyrene butyl rubber, EVA copolymers, and plasticized polymers.
- Claim 8: second layer thickness about 0.5–30 mil.
Design-around pressure point:
- Many pressure-sensitive adhesives can meet elongation/tensile thresholds depending on formulation. But if a competitor uses adhesives that do not satisfy these mechanical constraints, it can reduce risk for claim 6 specifically, not necessarily claim 1 unless those constraints are required by construction for independent claim 1 (they are not explicitly stated in claim 1 in your provided set).
Third layer cuts and thickness
- Claim 9: third layer thickness about 1–40 mil.
- Claim 12: third layer is a laminate of two polymer films.
This is the central architecture differentiator.
- Removing, eliminating, or changing the “cuts” concept (including location, depth, or definition of “at least partially through”) is the clearest design-around lever.
- If the third layer is not cut, or if cuts are formed only in the drug layer, or if the third layer remains uncut, independent claim 1/13 can be avoided.
Donepezil specificity
- Claim 10: drug is donepezil.
- Claim 13: delivery of donepezil through skin and includes a release liner.
- Claims 14–19: constrain first/second/third layer materials and thicknesses for the donepezil delivery method.
- Claim 20: release liner selection limited to silicone-coated or fluorocarbon or fluorosilicone-coated PET variants.
Design-around pressure point:
- A different release liner material may avoid dependent claim 20 but may not avoid claim 13 unless the release liner selection is treated as a limiting claim element (claim 13 requires a release liner but not the enumerated liner materials; claim 20 narrows liner chemistry).
How strong is the patent estate for transdermal donepezil: what is the “sweet spot” for infringement?
Most infringement-prone products
A transdermal patch designed for Alzheimer’s and delivering donepezil that uses:
- A backing stack containing:
- a stretchable polymer fabric/film layer,
- an adhesive polymer layer,
- a polymer film layer laminated to the drug layer,
- with cuts at least partially through the third film layer,
- and an adhesive matrix drug layer laminated to the cut-containing third film.
What does not need to match
In the independent claims as provided, the patch does not require:
- a specific drug loading amount,
- specific permeation enhancers,
- specific cut geometry (only “cuts” and “at least partially through”),
- specific release liner material (only present as a “release liner” element in claim 13).
That makes claim coverage architecture-driven, not purely formulation-driven.
What patent landscape typically surrounds this type of transdermal adhesive-cut backing architecture?
While this response is limited to the provided claim text for US 11,679,086, the landscape around transdermal donepezil patents generally clusters into four buckets that affect freedom-to-operate and litigation strategy:
- Active ingredient (donepezil) composition and polymorphs
- Transdermal delivery systems
- matrix vs reservoir designs
- adhesive chemistries
- penetration enhancer usage
- Backing and laminate structures
- breathable vs occlusive
- stretchable support layers
- liner and release layer stacks
- Manufacturing methods
- lamination steps
- cutting/slotting operations
- formation of cut patterns
US 11,679,086 is most directly positioned in bucket 3 (backing and laminate structures) with a method-of-use/delivery overlay.
In litigation posture terms: architecture-linked claims often force courts and experts to examine patch cross-sections and fabrication steps, which can be decisive for claim construction (what counts as “cuts,” what is “at least partially through,” how laminations are established).
What claims could be asserted in a generic or competitor scenario?
Scenario A: competitor sells a donepezil patch with cut-containing third film
- Claim 1 exposure: high if the patch matches the three-layer backing laminate arrangement and the cut-containing third film is present and laminated to the adhesive matrix drug layer.
- Claim 13 exposure: high if the patch includes a release liner and the product is marketed/used for delivery of donepezil through skin.
Scenario B: competitor makes an adhesive matrix patch without cut-containing third film
- Independent claims 1/13 risk drops because the cut-containing third layer is a required structural element.
- Dependent thickness and material composition claims become moot if the architecture anchor is missing.
Scenario C: competitor keeps cuts but changes backing stretchability
- If the first layer stretchability fails to meet ≥5%, claim 1 can fail on that property.
- Claim 3 provides material list constraints, but claim 1 still includes the stretchability requirement, so the property is still a key defense vector.
Scenario D: competitor uses different release liner
- Claim 20 risk can be designed out.
- Claim 13 requires only a release liner broadly, so it remains a possible asserted target if the rest of the architecture is the same.
Timing and exclusivity: when would this patent matter for generic entry?
This analysis requires knowing the patent’s grant date, priority date, and any related patents with term adjustments, terminal disclaimers, or patent term extensions. Your prompt provides the claim set but not the filing/prosecution timeline or the patent’s legal status. Without those dates, it is not possible to produce an accurate exclusivity and generic entry timing map.
What is the practical construction of “cuts formed at least partially through the layer”?
In high-stakes patch patent disputes, “cuts” usually become the focal factual issue. For US 11,679,086, infringement would likely be argued by showing:
- The third polymer film layer contains cut features,
- The cuts traverse the film to a depth that is “at least partially through,”
- The cut layer is in the stack in the required order so that the adhesive matrix drug layer is laminated to the cut-containing layer.
Design-around options typically pursued by patch makers include:
- confining cutting to another layer (drug layer or adhesive layer),
- using apertures or perforations that do not meet the “cut” characterization,
- leaving the third layer uncut while using mechanical compliance elsewhere.
Key Takeaways
- US 11,679,086 is architecturally anchored to a transdermal patch stack: stretchable first layer + adhesive second layer + cut-containing third polymer film laminated to an adhesive matrix drug layer.
- Cut depth and placement are the main infringement hinge for both independent claim 1 and delivery-focused claim 13.
- Donepezil specificity is explicit in dependent claim 10 and claims 13-20; claim 1 is broader in drug identity but still anchored to the same patch architecture.
- Design-around focus should prioritize removing or changing the cut-containing third film, altering first-layer stretchability, and choosing alternative release liner types to avoid dependent claim 20.
FAQs
-
Does US 11,679,086 require the third polymer film cuts to penetrate the entire film thickness?
No. The claim requires cuts “at least partially through,” which typically supports partial-depth penetration rather than full perforation.
-
Can a patch infringe if the cut features are in the adhesive layer rather than the third polymer film layer?
Based on the claim language, cuts must be in the third layer. Cutting only elsewhere weakens literal fit for claim 1/13.
-
What determines whether the “stretchability of at least 5%” limitation is met?
Material testing of the first polymer film/fabric’s elongation in at least one direction under defined test conditions.
-
Is a specific adhesive chemistry required to practice US 11,679,086?
Claim 1 requires adhesive polymers in the second layer but does not limit to a single chemistry; dependent claims enumerate specific adhesive polymer classes.
-
Does using a different release liner avoid the donepezil delivery method claim?
It may avoid dependent claim 20, but claim 13 still requires a release liner generally.
References (APA)
- United States Patent 11,679,086.
